OKT3 treatment in refractory pediatric heart transplant rejection.
暂无分享,去创建一个
W. Mahle | K. Kanter | R. Vincent | I. Wilmot | A. Berg
[1] W. Mahle,et al. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[2] J. Saffitz,et al. Non-ischemic left ventricular dysfunction after pediatric cardiac transplantation: treatment with plasmapheresis and OKT3. , 2004, The Journal of Heart and Lung Transplantation.
[3] S. Gundry,et al. Total lymphoid irradiation for refractory rejection in pediatric heart transplantation. , 2002, The Annals of thoracic surgery.
[4] J. Tomaszewski,et al. Successful reversal of severe refractory cardiac allograft rejection by photopheresis. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] R. Novick,et al. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[6] R. Hetzer,et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[7] D. Ivy,et al. Transplant coronary artery disease in pediatrics: favorable outcome with medical therapy. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[8] L. Bailey,et al. Late rejection is a predictor of transplant coronary artery disease in children. , 2001, Journal of the American College of Cardiology.
[9] P. McCarthy,et al. Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[10] C. Mavroudis,et al. Reversal of severe late left ventricular failure after pediatric heart transplantation and possible role of plasmapheresis. , 2000, The American journal of cardiology.
[11] R. Loertscher,et al. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. , 1997, Clinical transplantation.
[12] D. Renlund,et al. Methotrexate therapy in pediatric heart transplantation as treatment of recurrent mild to moderate acute cellular rejection. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[13] B. Meiser,et al. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation? , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[14] Y. Liao,et al. Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. , 1993, Transplantation proceedings.
[15] R. Fisher,et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.
[16] M. Hammond,et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. , 1990, The Journal of heart transplantation.
[17] A. Menter,et al. Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent. , 1990, Archives of internal medicine.
[18] B. Radovancević,et al. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation. , 1989, The Journal of heart transplantation.
[19] B. McManus,et al. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience. , 1989, The Journal of heart transplantation.
[20] J. Sinnott,et al. The treatment of advanced cardiac allograft rejection. , 1988, The Annals of thoracic surgery.
[21] L. Gray,et al. USE OF OKT3 MONOCLONAL ANTIBODY IN THE TREATMENT OF ACUTE CARDIAC ALLOGRAFT REJECTION , 1988, Transplantation.